US7750006B2 - Phthalazinone derivatives - Google Patents
Phthalazinone derivatives Download PDFInfo
- Publication number
- US7750006B2 US7750006B2 US11/352,178 US35217806A US7750006B2 US 7750006 B2 US7750006 B2 US 7750006B2 US 35217806 A US35217806 A US 35217806A US 7750006 B2 US7750006 B2 US 7750006B2
- Authority
- US
- United States
- Prior art keywords
- yield
- purity
- group
- groups
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 0 CC1=NN(C)C(=O)C2=C1B*2 Chemical compound CC1=NN(C)C(=O)C2=C1B*2 0.000 description 21
- WRDDMOMACIOBIN-UHFFFAOYSA-N CCCC(=O)NC1=CC(CC2=NNC(=O)C3=C2C=CC=C3)=CC=C1 Chemical compound CCCC(=O)NC1=CC(CC2=NNC(=O)C3=C2C=CC=C3)=CC=C1 WRDDMOMACIOBIN-UHFFFAOYSA-N 0.000 description 1
- ADOLOKADABMXGK-UHFFFAOYSA-M CF.FF.NC1=CC=C(CC2=NNC(=O)C3=CC=CC=C32)C=C1.O=C(NC1=CC=C(CC2=NNC(=O)C3=CC=CC=C32)C=C1)C1=CC=C(F)C=C1.[F-] Chemical compound CF.FF.NC1=CC=C(CC2=NNC(=O)C3=CC=CC=C32)C=C1.O=C(NC1=CC=C(CC2=NNC(=O)C3=CC=CC=C32)C=C1)C1=CC=C(F)C=C1.[F-] ADOLOKADABMXGK-UHFFFAOYSA-M 0.000 description 1
- LNXYXWZOZAIFNI-UHFFFAOYSA-N CN(C)CC1=CC=CC(C(=O)NC2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2N2CCOCC2)=C1.ClCOC1=CC=CC(CCl)=C1.NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1.O=C(NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1)C1=CC(CCl)=CC=C1 Chemical compound CN(C)CC1=CC=CC(C(=O)NC2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2N2CCOCC2)=C1.ClCOC1=CC=CC(CCl)=C1.NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1.O=C(NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1)C1=CC(CCl)=CC=C1 LNXYXWZOZAIFNI-UHFFFAOYSA-N 0.000 description 1
- BLRBFNSVQIIZFN-UHFFFAOYSA-N COC(=O)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1.O=C(O)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1 Chemical compound COC(=O)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1.O=C(O)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1 BLRBFNSVQIIZFN-UHFFFAOYSA-N 0.000 description 1
- KWEZVFWFZLYGOM-UHFFFAOYSA-N COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1F.COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1F Chemical compound COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1F.COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1F KWEZVFWFZLYGOM-UHFFFAOYSA-N 0.000 description 1
- LQZMHVFIWNVVII-UHFFFAOYSA-N COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1O.COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1O.COC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1OCC1=CC=CC=C1 LQZMHVFIWNVVII-UHFFFAOYSA-N 0.000 description 1
- QHSFXHZNKBNKJJ-UHFFFAOYSA-N NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1.O=C(CCCCl)NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1.O=C(Cl)CCCCl Chemical compound NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1.O=C(CCCCl)NC1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1N1CCOCC1.O=C(Cl)CCCCl QHSFXHZNKBNKJJ-UHFFFAOYSA-N 0.000 description 1
- CZHMABYGCRGQQE-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1.O=C(O)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1.O=C(O)C1=CC(CC2=NNC(=O)C3=CC=CC=C32)=CC=C1 CZHMABYGCRGQQE-UHFFFAOYSA-N 0.000 description 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N O=C1NN=CC2=C1C=CC=C2 Chemical compound O=C1NN=CC2=C1C=CC=C2 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to phthalazinone derivatives, and their use as pharmaceuticals.
- the present invention relates to the use of these compounds to inhibit the activity of the enzyme poly (ADP-ribose)polymerase, also known as poly(ADP-ribose)synthase and poly ADP-ribosyltransferase, and commonly referred to as PARP.
- poly (ADP-ribose)polymerase also known as poly(ADP-ribose)synthase and poly ADP-ribosyltransferase, and commonly referred to as PARP.
- the mammalian enzyme PARP (a 113-kDa multidomain protein) has been implicated in the signalling of DNA damage through its ability to recognize and rapidly bind to DNA single or double strand breaks (D'Amours et al, 1999, Biochem. J. 342: 249-268).
- Poly (ADP-ribosyl)ation has also been associated with malignant transformation.
- PARP activity is higher in the isolated nuclei of SV40-transformed fibroblasts, while both leukemic cells and colon cancer cells show higher enzyme activity than the equivalent normal leukocytes and colon mucosa (Miwa et al, 1977, Arch. Biochem. Biophys. 181: 313-321; Burzio et al, 1975, Proc. Soc. Exp. Bioi. Med. 149: 933-938; and Hirai et al, 1983, Cancer Res. 43: 3441-3446).
- a number of low-molecular-weight inhibitors of PARP have been used to elucidate the functional role of poly (ADP-ribosyl)ation in DNA repair.
- the inhibition of PARP leads to a marked increase in DNA-strand breakage and cell killing (Durkacz et al, 1980, Nature 283: 593-596; Berger, N. A., 1985, Radiation Research, 101: 4-14).
- PARP knockout (PARP ⁇ / ⁇ ) animals exhibit genomic instability in response to alkylating agents and ⁇ -irradiation (Wang et al, 1995, Genes Dev., 9: 509-520; Menissier de Murcia et al, 1997, Proc. Natl. Acad. Sci. USA, 94: 7303-7307).
- PARP has been demonstrated to play a role in the pathogenesis of haemorrhagic shock (Liaudet et al, 2000, Proc. Natl. Acad. Sci. U.S.A., 97(3): 10203-10208).
- PARP inhibition has been speculated to delay the onset of aging characteristics in human fibroblasts (Rattan and Clark, 1994, Biochem. Biophys. Res. Comm., 201 (2): 665-672). This may be related to the role that PARP plays in controlling telomere function (d'Adda di Fagagna et al, 1999, Nature Gen., 23(1): 76-80).
- the first aspect of the present invention provides a method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula:
- R C is represented by -L-R L , where L is of formula: —(CH 2 ) n1 -Q n2 -(CH 2 ) n3 — wherein n 1 , n 2 and n 3 are each selected from 0, 1, 2 and 3, the sum of n 1 , n 2 and n 3 is 1, 2 or 3 and Q is selected from O, S, NH, C( ⁇ O) or —CR 1 R 2 —, where R 1 and R 2 are independently selected from hydrogen, halogen or optionally substituted C 1-7 alkyl, or may together with the carbon atom to which they are attached form a C 3-7 cyclic alkyl group, which may be saturated (a C 3-7 cycloalkyl group) or unsaturated (a C 3-7 cycloalkenyl group), or one of R 1 and
- a second aspect of the present invention relates to a compound of the formula:
- R C is —CH 2 —R L ;
- R L is optionally substituted phenyl; and
- R N is hydrogen.
- a third aspect of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the second aspect and a pharmaceutically acceptable carrier or diluent.
- the disease mediated by PARP is: vascular disease; septic shock; ischaemic injury; neurotoxicity; haemorraghic shock; or viral infection.
- a further aspect of the invention provides a method of cancer therapy for the human or animal body comprising administering to such a subject a therapeutically effective amount of a compound as described in the first aspect in combination with chemotherapy or radiation therapy.
- Another further aspect of the invention provides a method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound as described in the first aspect of the invention. Such a method may be practised in vivo or in vitro.
- a compound when administered it is done so in the form of a pharmaceutical composition it is done so in the form of a pharmaceutical composition.
- FIGS. 1 to 19 show compounds according to the present invention.
- aromatic ring is used herein in the conventional sense to refer to a cyclic aromatic structure, that is, a cyclic structure having delocalised ⁇ -electron orbitals.
- the aromatic ring fused to the main core i.e. that formed by -A-B-, may bear further fused aromatic rings (resulting in, e.g. naphthyl or anthracenyl groups).
- the aromatic ring(s) may comprise solely carbon atoms, or may comprise carbon atoms and one or more heteroatoms, including but not limited to, nitrogen, oxygen, and sulfur atoms.
- the aromatic ring(s) preferably have five or six ring atoms.
- the aromatic ring(s) may optionally be substituted. If a substituent itself comprises an aryl group, this aryl group is not considered to be a part of the aryl group to which it is attached.
- the group biphenyl is considered herein to be a phenyl group (an aryl group comprising a single aromatic ring) substituted with a phenyl group.
- the group benzylphenyl is considered to be a phenyl group (an aryl group comprising a single aromatic ring) substituted with a benzyl group.
- the aromatic group comprises a single aromatic ring, which has five or six ring atoms, which ring atoms are selected from carbon, nitrogen, oxygen, and sulfur, and which ring is optionally substituted.
- these groups include benzene, pyrazine, pyrrole, thiazole, isoxazole, and oxazole.
- 2-Pyrone can also be considered to be an aromatic ring, but is less preferred.
- the aromatic ring has six atoms, then preferably at least four, or even five or all, of the ring atoms are carbon.
- the other ring atoms are selected from nitrogen, oxygen and sulphur, with nitrogen and oxygen being preferred.
- Suitable groups include a ring with: no hetero atoms (benzene); one nitrogen ring atom (pyridine); two nitrogen ring atoms (pyrazine, pyrimidine and pyridazine); one oxygen ring atom (pyrone); and one oxygen and one nitrogen ring atom (oxazine).
- Suitable rings include a ring with: one nitrogen ring atom (pyrrole); two nitrogen ring atoms (imidazole, pyrazole); one oxygen ring atom (furan); one sulphur ring atom (thiophene); one nitrogen and one sulphur ring atom (thiazole); and one nitrogen and one oxygen ring atom (isoxazole or oxazole).
- the aromatic ring may bear one or more substituent groups at any available ring position. These substituents are selected from halo, nitro, hydroxy, ether, thiol, thioether, amino, C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl.
- the aromatic ring may also bear one or more substituent groups which together form a ring. In particular these may be of formula —(CH 2 ) m — or —O—(CH 2 ) p —O—, where m is 2, 3, 4 or 5 and p is 1, 2 or 3.
- C 1-7 alkyl refers to a monovalent moiety obtained by removing a hydrogen atom from a C 1-7 hydrocarbon compound having from 1 to 7 carbon atoms, which may be aliphatic or alicyclic, or a combination thereof, and which may be saturated, partially unsaturated, or fully unsaturated.
- Examples of (unsubstituted) saturated linear C 1-7 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, and n-pentyl (amyl).
- Examples of (unsubstituted) saturated branched C 1-7 alkyl groups include, but are not limited to, iso-propyl, iso-butyl, sec-butyl, tert-butyl, and neo-pentyl.
- saturated alicyclic (carbocyclic) C 1-7 alkyl groups include, but are not limited to, unsubstituted groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, as well as substituted groups (e.g., groups which comprise such groups), such as methylcyclopropyl, dimethylcyclopropyl, methylcyclobutyl, dimethylcyclobutyl, methylcyclopentyl, dimethylcyclopentyl, methylcyclohexyl, dimethylcyclohexyl, cyclopropylmethyl and cyclohexylmethyl.
- Examples of (unsubstituted) unsaturated C 1-7 alkyl groups which have one or more carbon-carbon double bonds include, but are not limited to, ethenyl (vinyl, —CH ⁇ CH 2 ), 2-propenyl (allyl, —CH 2 —CH ⁇ CH 2 ), isopropenyl (—C(CH 3 ) ⁇ CH 2 ), butenyl, pentenyl, and hexenyl.
- C 1-7 alkyl groups which have one or more carbon-carbon triple bonds
- C 2-7 alkynyl groups include, but are not limited to, ethynyl (ethinyl) and 2-propynyl (propargyl).
- Examples of unsaturated alicyclic (carbocyclic) C 1-7 alkyl groups which have one or more carbon-carbon double bonds include, but are not limited to, unsubstituted groups such as cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl, as well as substituted groups (e.g., groups which comprise such groups) such as cyclopropenylmethyl and cyclohexenylmethyl.
- C 3-20 heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a non-aromatic C 3-20 heterocyclic compound, said compound having one ring, or two or more rings (e.g., spiro, fused, bridged), and having from 3 to 20 ring atoms, atoms, of which from 1 to 10 are ring heteroatoms, and wherein at least one of said ring(s) is a heterocyclic ring.
- each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.
- “C 3-20 ” denotes ring atoms, whether carbon atoms or heteroatoms.
- C 3-20 heterocyclyl groups having one nitrogen ring atom include, but are not limited to, those derived from aziridine, azetidine, azetine, pyrrolidine, pyrroline, piperidine, dihydropyridine, tetrahydropyridine, and dihydropyrrole (azoline).
- C 3-20 heterocyclyl groups having one oxygen ring atom include, but are not limited to, those derived from oxirane, oxetane, oxolane (tetrahydrofuran), oxole (dihydrofuran), oxane (tetrahydropyran), dihydropyran, and pyran.
- substituted C 3-20 heterocyclyl groups include sugars, in cyclic form, for example, furanoses and pyranoses, including, for example, ribose, lyxose, xylose, galactose, sucrose, fructose, and arabinose.
- C 3-20 heterocyclyl groups having one sulfur ring atom include, but are not limited to, those derived from thiolane (tetrahydrothiophene, thiane) and tetrahydrothiopyran.
- C 3-20 heterocyclyl groups having two oxygen ring atoms include, but are not limited to, those derived from dioxane, for example 1,3-dioxane and 1,4-dioxane.
- C 3-20 heterocyclyl groups having two nitrogen ring atoms include, but are not limited to, those derived from diazolidine (pyrazolidine), pyrazoline, imidazolidine, imidazoline, and piperazine.
- C 3-20 heterocyclyl groups having one nitrogen ring atom and one oxygen ring atom include, but are not limited to, those derived from tetrahydrooxazole, dihydrooxazole, tetrahydroisoxazole, dihydroisoxazole, morpholine, tetrahydrooxazine, dihydrooxazine, and oxazine.
- C 3-20 heterocyclyl groups having one oxygen ring atom and one sulfur ring atom include, but are not limited to, those derived from oxathiolane and oxathiane.
- C 3-20 heterocyclyl groups having one nitrogen ring atom and one sulfur ring atom include, but are not limited to, those derived from thiazoline, thiazolidine, and thiomorpholine.
- C 3-20 heterocyclyl groups include, but are not limited to, oxadiazine.
- the substituents are on carbon, or nitrogen (if present), atoms.
- C 5-20 aryl refers to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of a C 5-20 aromatic compound, said compound having one ring, or two or more rings (e.g., fused), and having from 5 to 20 ring atoms, and wherein at least one of said ring(s) is an aromatic ring.
- each ring has from 5 to 7 ring atoms.
- the ring atoms may be all carbon atoms, as in “carboaryl groups” in which case the group may conveniently be referred to as a “C 5-20 carboaryl” group.
- C 5-20 aryl groups which do not have ring heteroatoms include, but are not limited to, those derived from benzene (i.e., phenyl) (C 6 ), naphthalene (C 10 ), anthracene (C 14 ), phenanthrene (C 14 ), and pyrene (C 16 ).
- the ring atoms may include one or more heteroatoms, including but not limited to oxygen, nitrogen, and sulfur, as in “heteroaryl groups”.
- the group may conveniently be referred to as a “C 5-20 heteroaryl” group, wherein “C 5-20 ” denotes ring atoms, whether carbon atoms or heteroatoms.
- each ring has from 5 to 7 ring atoms, of which from 0 to 4 are ring heteroatoms.
- C 5-20 heteroaryl groups include, but are not limited to, C 5 heteroaryl groups derived from furan (oxole), thiophene (thiole), pyrrole (azole), imidazole (1,3-diazole), pyrazole (1,2-diazole), triazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, and oxatriazole; and C 6 heteroaryl groups derived from isoxazine, pyridine (azine), pyridazine (1,2-diazine), pyrimidine (1,3-diazine; e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine), triazine, tetrazole, and oxadiazole (furazan).
- C 5 heteroaryl groups derived from furan (oxole), thi
- the heteroaryl group may be bonded via a carbon or hetero ring atom.
- C 5-20 heteroaryl groups which comprise fused rings include, but are not limited to, C 9 heteroaryl groups derived from benzofuran, isobenzofuran, benzothiophene, indole, isoindole; C 10 heteroaryl groups derived from quinoline, isoquinoline, benzodiazine, pyridopyridine; C 14 heteroaryl groups derived from acridine and xanthene.
- Halo —F, —Cl, —Br, and —I.
- Ether —OR, wherein R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a C 1-7 alkoxy group), a C 3-20 heterocyclyl group (also referred to as a C 3-20 heterocyclyloxy group), or a C 5-20 aryl group (also referred to as a C 5-20 aryloxy group), preferably a C 1-7 alkyl group.
- R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a C 1-7 alkoxy group), a C 3-20 heterocyclyl group (also referred to as a C 3-20 heterocyclyloxy group), or a C 5-20 aryl group (also referred to as a C 5-20 aryloxy group), preferably a C 1-7 alkyl group.
- R is an acyl substituent, for example, a C 1-7 alkyl group (also referred to as C 1-7 alkylacyl or C 1-7 alkanoyl), a C 3-20 heterocyclyl group (also referred to as C 3-20 heterocyclylacyl), or a C 5-20 aryl group (also referred to as C 5-20 arylacyl), preferably a C 1-7 alkyl group.
- R is an acyl substituent, for example, a C 1-7 alkyl group (also referred to as C 1-7 alkylacyl or C 1-7 alkanoyl), a C 3-20 heterocyclyl group (also referred to as C 3-20 heterocyclylacyl), or a C 5-20 aryl group (also referred to as C 5-20 arylacyl), preferably a C 1-7 alkyl group.
- acyl groups include, but are not limited to, —C( ⁇ O)CH 3 (acetyl), —C( ⁇ O)CH 2 CH 3 (propionyl), —C( ⁇ O)C(CH 3 ) 3 (butyryl), and —C( ⁇ O)Ph (benzoyl, phenone).
- Ester (carboxylate, carboxylic acid ester, oxycarbonyl): —C( ⁇ O)OR, wherein R is an ester substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a C 1-7 alkyl group.
- ester groups include, but are not limited to, —C( ⁇ O)OCH 3 , —C( ⁇ O)OCH 2 CH 3 , —C( ⁇ O)OC(CH 3 ) 3 , and —C( ⁇ O)OPh.
- amido groups include, but are not limited to, —C( ⁇ O)NH 2 , —C( ⁇ O)NHCH 3 , —C( ⁇ O)N(CH 3 ) 2 , —C( ⁇ O)NHCH 2 CH 3 , and —C( ⁇ O)N(CH 2 CH 3 ) 2 , as well as amido groups in which R 1 and R 2 , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.
- R 1 and R 2 are independently amino substituents, for example, hydrogen, a C 1-7 alkyl group (also referred to as C 1-7 alkylamino or di-C 1-7 alkylamino), a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably H or a C 1-7 alkyl group, or, in the case of a “cyclic” amino group, R 1 and R 2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms.
- R 1 and R 2 are independently amino substituents, for example, hydrogen, a C 1-7 alkyl group (also referred to as C 1-7 alkylamino or di-C 1-7 alkylamino), a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably H or a C 1-7 alkyl group, or, in the case of a “cyclic” amino group, R 1 and R 2 ,
- amino groups include, but are not limited to, —NH 2 , —NHCH 3 , —NHCH(CH 3 ) 2 , —N(CH 3 ) 2 , —N(CH 2 CH 3 ) 2 , and —NHPh.
- cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, perhydrodiazepino, morpholino, and thiomorpholino.
- the cyclic amino groups may be substituted on their ring by any of the substituents defined here, for example carboxy, carboxylate and amido.
- a particular form of amino group is where one of R 1 and R 2 is a sulfone (—S( ⁇ O) 2 R), where R is a sulfone substituent, and this group can be termed a sulfonamido group.
- sulfonamido groups include, but are not limited to, —NHS( ⁇ O) 2 CH 3 , —NHS( ⁇ O) 2 Ph and —NHS( ⁇ O) 2 C 6 H 4 F.
- acylamide groups include, but are not limited to, —NHC( ⁇ O)CH 3 , —NHC( ⁇ O)CH 2 CH 3 , and —NHC( ⁇ O)Ph.
- R 2 is an amino group (—NR 3 R 4 ), where R 3 and R 4 are independently amino substituents, as this group can be termed an ureido group.
- ureido groups include, but are not limited to —NHC( ⁇ O)NHCH 3 , —NHC( ⁇ O)NHCH 2 CH 3 , and —NHC( ⁇ O)NHPh.
- R is an acyloxy substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a C 1-7 alkyl group.
- acyloxy groups include, but are not limited to, —OC( ⁇ O)CH 3 (acetoxy), —OC( ⁇ O)CH 2 CH 3 , —OC( ⁇ O)C(CH 3 ) 3 , —OC( ⁇ O) Ph, —OC( ⁇ O)C 6 H 4 F, and —OC( ⁇ O)CH 2 Ph.
- C 1-7 alkylthio groups include, but are not limited to, —SCH 3 and —SCH 2 CH 3 .
- R is a sulfoxide substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a C 1-7 alkyl group.
- sulfoxide groups include, but are not limited to, —S( ⁇ O)CH 3 and —S( ⁇ O)CH 2 CH 3 .
- R is a sulfone substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a C 1-7 alkyl group.
- sulfone groups include, but are not limited to, —S( ⁇ O) 2 CH 3 (methanesulfonyl, mesyl), —S( ⁇ O) 2 CF 3 , —S( ⁇ O) 2 CH 2 CH 3 , and 4-methylphenylsulfonyl (tosyl).
- a substituent on a ring which forms part of R C and a substituent on the fused aromatic ring may together form an intra ring link, thus forming a further cyclic structure in the compound.
- the substituent on the aromatic ring that forms the intra ring link is preferably on the atom adjacent the central moiety (i.e. at the ⁇ -position).
- the substituent on R C that forms the intra ring link is preferably on the atom which is one atom away from the atom which is bound to the central moiety.
- the link between the two rings may be a single bond, or may be of the formula: —(CH n2 ) n1′ -Q′ n2′ -(CH 2 ) n3′ — wherein n1′, n2′ and n3′ are each selected from 0, 1, 2 and 3 and the sum of n1′, n2′ and n3′ is less than or equal to 3.
- Q′ can be O, S, NH or C( ⁇ O).
- the fused aromatic ring(s) represented by -A-B- preferably consist of solely carbon ring atoms, and thus may be benzene, naphthalene, and is more preferably benzene. As described above, these rings may be substituted, but in some embodiments are preferably unsubstituted.
- R N is preferably selected from hydrogen, and amido.
- R N is preferably amido, where one amido substituent is phenyl, optionally substituted by fluorine, preferably in the para position.
- R N is preferably H.
- each Q (if n2 is greater than 1) is selected from O, S, NH or C( ⁇ O).
- L is preferably of formula:
- n1 is selected from 0, 1, 2 and 3 and n2 is selected from 0 and 1 (where the sum of n1 and n2 is 1, 2 or 3), and more preferably n2 is 0.
- n1 is preferably 1 or 2, more preferably 1.
- the most preferred option for L is —CH 2 —.
- n2 is preferably 1.
- R 1 is optionally substituted C 1-7 alkyl and R 2 is hydrogen.
- R 1 is more preferably optionally substituted C 1-4 alkyl, and most preferably unsubstituted C 1-4 alkyl.
- R 1 and R 2 together with the carbon atom to which they are attached, form a saturated C 3-7 cyclic alkyl group, more preferably a C 5-7 cyclic alkyl group.
- R 1 is attached to an atom in R L to form an unsaturated C 3-7 cycloalkenyl group, more preferably a C 5-7 cycloalkenyl group, which comprises the carbon atoms to which R 1 and R 2 are attached in Q, —(CH 2 ) n3 — (if present) and part of R L , and R 2 is hydrogen.
- R L is preferably a benzene ring, naphthalene, pyridine or 1,3-benzodioxole, and more preferably a benzene ring.
- R L is a benzene ring, it is preferably substituted.
- the one or more substituents may be selected from: C 1-7 alkyl, more preferably methyl, CF 3 ; C 5-20 aryl; C 3-20 heterocyclyl; halo, more preferably fluoro; hydroxy; ether, more preferably methoxy, phenoxy, benzyloxy, and cyclopentoxy; nitro; cyano; carbonyl groups, such as carboxy, ester and amido; amino (including sulfonamido), more preferably —NH 2 , —NHPh, and cycloamino groups, such as morpholino; acylamido, including ureido groups, where the acyl or amino substituent is preferably phenyl, which itself is optionally fluorinated; acyloxy; thiol; thioether; sulfoxide; sulfone.
- fluoro is particularly preferred as a substituent, along with substituents containing a phenyl, or fluorinated phenyl, component.
- Preferred substituents of the benzene ring, when R L is phenyl, include:
- acylamido wherein the amide substituent is selected from C 1-7 alkyl, C 3-20 heterocyclyl, and C 5-20 aryl, more preferably C 1-7 alkyl and C 5-20 aryl, which groups are optionally further substituted.
- the optional substituents may be selected from any of those listed above, but those of particular interest include C 1-7 alkyl and C 5-20 aryl groups, halo, ether, thioether and sulfone groups; (ii) ureido, where one amine substituent is preferably hydrogen, and the other is selected from C 1-7 alkyl, C 3-20 heterocyclyl, and C 5-20 aryl, more preferably C 1-7 alkyl and C 5-20 aryl, which groups are optionally further substituted.
- the optional substituents may be selected from any of those listed above, but those of particular interest include C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, halo and ether groups; (iii) sulfonamino, wherein the amine substituent is preferably hydrogen and the sulfone substituent is selected from C 1-7 alkyl, C 3-20 heterocyclyl, and C 5-20 aryl, more preferably C 1-7 alkyl and C 5-20 aryl, which groups are optionally further substituted.
- the optional substituents may be selected from any of those listed above, but those of particular interest include C 5-20 aryl groups and acylamido groups; (iv) acyloxy, wherein the acyloxy substituent is selected from C 1-7 alkyl, C 3-20 heterocyclyl, and C 5-20 aryl, more preferably C 1-7 alkyl and C 5-20 aryl, which groups are optionally further substituted.
- the optional substituents may be selected from any of those listed above, but those of particular interest include C 1-7 alkyl and C 5-20 aryl groups, halo, ether, thioether, sulfone and nitro groups.
- a and B together represent a substituted fused aromatic ring it is preferred that the substituent does not form an intra ring link with a substituent on a ring which forms part of R c . Substituents in the five position are particularly preferred.
- a reference to carboxylic acid also includes the anionic (carboxylate) form (—COO ⁇ ), a salt or solvate thereof, as well as conventional protected forms.
- a reference to an amino group includes the protonated form (—N + HR 1 R 2 ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group.
- a reference to a hydroxyl group also includes the anionic form (—O ⁇ ), a salt or solvate thereof, as well as conventional protected forms of a hydroxyl group.
- Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and ( ⁇ ) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; ⁇ - and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as “isomers” (or “isomeric forms”).
- the compound is in crystalline form, it may exist in a number of different polymorphic forms.
- isomers are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
- a reference to a methoxy group, —OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, —CH 2 OH.
- a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
- a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C 1-7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
- C 1-7 alkyl includes n-propyl and iso-propyl
- butyl includes n-, iso-, sec-, and tert-butyl
- methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl
- keto-, enol-, and enolate-forms as in, for example, the following tautomeric pairs: keto/enol, imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro.
- H may be in any isotopic form, including 1 H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
- a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof.
- Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
- a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below, as well as its different polymorphic forms.
- a corresponding salt of the active compound for example, a pharmaceutically-acceptable salt.
- a pharmaceutically-acceptable salt examples are discussed in Berge et al., 1977, “Pharmaceutically Acceptable Salts,” J. Pharm. Sci ., Vol. 66, pp. 1-19.
- a salt may be formed with a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
- Suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
- suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
- An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
- a salt may be formed with a suitable anion.
- suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
- Suitable organic anions include, but are not limited to, those derived from the following organic acids: acetic, propionic, succinic, gycolic, stearic, palmitic, lactic, malic, pamoic, tartaric, citric, gluconic, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, aspartic, benzoic, cinnamic, pyruvic, salicyclic, sulfanilic, 2-acetyoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanesulfonic, ethane disulfonic, oxalic, isethionic, valeric, and gluconic.
- suitable polymeric anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
- solvate is used herein in the conventional sense to refer to a complex of solute (e.g., active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
- chemically protected form pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions, that is, are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group).
- a protected or protecting group also known as a masked or masking group or a blocked or blocking group.
- a hydroxy group may be protected as an ether (—OR) or an ester (—OC( ⁇ O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (—OC( ⁇ O)CH 3 , —OAc).
- an aldehyde or ketone group may be protected as an acetal or ketal, respectively, in which the carbonyl group (>C ⁇ O) is converted to a diether (>C(OR) 2 ), by reaction with, for example, a primary alcohol.
- the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
- an amine group may be protected, for example, as an amide or a urethane, for example, as: a methyl amide (—NHCO—CH 3 ); a benzyloxy amide (—NHCO—OCH 2 C 6 H 5 , —NH-Cbz); as a t-butoxy amide (—NHCO—OC(CH 3 ) 3 , —NH-Boc); a 2-biphenyl-2-propoxy amide (—NHCO—OC(CH 3 ) 2 C 6 H 4 C 6 H 5 , —NH-Bpoc), as a 9-fluorenylmethoxy amide (—NH-Fmoc), as a 6-nitroveratryloxy amide (—NH-Nvoc), as a 2-trimethylsilylethyloxy amide (—NH-Teoc), as a 2,2,2-trichloroethyloxy amide (—NH-Troc), as an allyloxy amide (—NH-All
- a carboxylic acid group may be protected as an ester for example, as: an C 1-7 alkyl ester (e.g. a methyl ester; a t-butyl ester); a C 1-7 haloalkyl ester (e.g. a C 1-7 trihaloalkyl ester); a triC 1-7 alkylsilyl-C 1-7 alkyl ester; or a C 5-20 aryl-C 1-7 alkyl ester (e.g. a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.
- an C 1-7 alkyl ester e.g. a methyl ester; a t-butyl ester
- a C 1-7 haloalkyl ester e.g. a C 1-7 trihaloalkyl ester
- a triC 1-7 alkylsilyl-C 1-7 alkyl ester
- a thiol group may be protected as a thioether (—SR), for example, as: a benzyl thioether; an acetamidomethyl ether (—S—CH 2 NHC( ⁇ O)CH 3 ).
- SR thioether
- benzyl thioether an acetamidomethyl ether (—S—CH 2 NHC( ⁇ O)CH 3 ).
- prodrug refers to a compound which, when metabolised (e.g. in vivo), yields the desired active compound.
- the prodrug is inactive, or less active than the active compound, but may provide advantageous handling, administration, or metabolic properties.
- some prodrugs are esters of the active compound (e.g. a physiologically acceptable metabolically labile ester).
- the ester group (—C( ⁇ O)OR) is cleaved to yield the active drug.
- esters may be formed by esterification, for example, of any of the carboxylic acid groups (—C( ⁇ O)OH) in the parent compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required.
- Examples of such metabolically labile esters include those wherein R is C 1-7 alkyl (e.g. -Me, -Et); C 1-7 aminoalkyl (e.g.
- acyloxy-C 1-7 alkyl e.g. acyloxymethyl; acyloxyethyl; e.g.
- pivaloyloxymethyl acetoxymethyl; 1-acetoxyethyl; 1-(1-methoxy-1-methyl)ethyl-carbonxyloxyethyl; 1-(benzoyloxy)ethyl; isopropoxy-carbonyloxymethyl; 1-isopropoxy-carbonyloxyethyl; cyclohexyl-carbonyloxymethyl; 1-cyclohexyl-carbonyloxyethyl; cyclohexyloxy-carbonyloxymethyl; 1-cyclohexyloxy-carbonyloxyethyl; (4-tetrahydropyranyloxy) carbonyloxymethyl; 1-(4-tetrahydropyranyloxy)carbonyloxyethyl; (4-tetrahydropyranyl)carbonyloxymethyl; and 1-(4-tetrahydropyranyl)carbonyloxyethyl).
- prodrug forms include phosphonate and glycolate salts.
- hydroxy groups (—OH)
- —OH can be made into phosphonate prodrugs by reaction with chlorodibenzylphosphite, followed by hydrogenation, to form a phosphonate group —O—P( ⁇ O)(OH) 2 .
- Such a group can be cleared by phosphotase enzymes during metabolism to yield the active drug with the hydroxy group.
- prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound.
- the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
- a key step in the synthesis of these compounds is the addition/insertion of hydrazine, thus providing the adjacent nitrogen ring atoms in the central moiety.
- This addition of hydrazine is accomplished in particular by a ring insertion step in the routes exemplified below.
- the formed aromatic ring (represented by -A-B-) is usually derivatised before the routes shown below, and starting materials with the desired structure and substituent pattern are either commercially available or readily synthesised.
- Route 2 exemplifies a strategy where the aromatic ring is already substituted at the beginning of the synthesis route.
- n-Butyllithium (1.6M solution in hexane; 200 ml, 0.32 mol) was added dropwise under nitrogen at ⁇ 10° C. to a stirred solution of N-(2-methoxyphenyl)pivalamide (27.6 g, 0.133 mol) in tetrahydrofuran (600 ml), the mixture was allowed to warm to ambient temperature, stirred for a further 2 hours, then it was added to a large excess of crushed solid carbon dioxide. The mixture was allowed to warm to ambient temperature, 3M hydrochloric acid (200 ml) was added and the tetrahydrofuran was removed in vacuo.
- a stirred mixture of 3-methoxy-2-pivalamidobenzoic acid (20 g, 0.08 mol) and 7M hydrochloric acid (280 ml) was heated under reflux for 2 hours then cooled to 0° C.
- a solution of sodium nitrite (5.8 g, 0.09 mol) in water (46 ml) was added dropwise at ⁇ 5° C., the mixture was stirred at 0-5° C. for 2 hours, then a solution of potassium iodide (17.8 g, 0.11 mol) in water (39 ml) was added dropwise at 0-5° C.
- the stirred mixture was heated at 70-80° C. for 2 hours then cooled in ice.
- the appropriately substituted phenylacetylene (0.063 mol) was added at ambient temperature under nitrogen to a stirred solution of copper(I) iodide (0.1 g, 6.3 mmol), bis(triphenylphosphine)palladium(II) dichloride (0.43 g, 6.3 mmol), and methyl 2-iodo-3-methoxybenzoate (18.5 g, 0.063 mol) in triethylamine (375 ml), the mixture was stirred at ambient temperature for 72 hours, then it was added to 5M hydrochloric acid (1000 ml).
- substitution of the aromatic ring in the starting material can be altered as appropriate.
- Lithium hexamethyldisilazide (1M solution in hexanes; 33 ml, 0.033 mol) was added dropwise under nitrogen at ⁇ 78° C. to a stirred solution of dimethyl 3-oxobenzo[c]furan-1-ylphosphonate (8 g, 0.033 mol) or equivalent in tetrahydrofuran (300 ml), then the mixture was stirred at ⁇ 78° C. for 1 hour.
- the appropriate aryl alkyl ketone (0.03 mol) was added, the mixture was stirred at ⁇ 78° C. for 1 hour, allowed to warm to 0° C., then it was quenched by the addition of an excess of saturated aqueous ammonium chloride solution.
- the acylation is generally carried out by the addition of the appropriate acid chloride to the hydroxybenzylphthalazinone under suitable conditions. Examples of this are given below:
- the residue was purified to give the required ester.
- the purification was carried out via preparative scale HPLC on a Gilson LC using a Jones Chromatography Genesis 4 ⁇ C18 column using gradient elution between aqueous trifluoroacetic acid and acetonitrile as eluents.
- the present invention provides active compounds, specifically, active in inhibiting the activity of PARP.
- active pertains to compounds which are capable of inhibiting PARP activity, and specifically includes both compounds with intrinsic activity (drugs) as well as prodrugs of such compounds, which prodrugs may themselves exhibit little or no intrinsic activity.
- the present invention further provides a method of inhibiting the activity of PARP in a cell, comprising contacting said cell with an effective amount of an active compound, preferably in the form of a pharmaceutically acceptable composition. Such a method may be practised in vitro or in vivo.
- a sample of cells may be grown in vitro and an active compound brought into contact with said cells, and the effect of the compound on those cells observed.
- effect the amount of DNA repair effected in a certain time may be determined.
- the active compound is found to exert an influence on the cells, this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type.
- treatment pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition.
- Treatment as a prophylactic measure i.e., prophylaxis is also included.
- adjunct as used herein relates to the use of active compounds in conjunction with known therapeutic means. Such means include cytotoxic regimes of drugs and/or ionising radiation as used in the treatment of different cancer types.
- terapéuticaally-effective amount pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio.
- Active compounds may also be used as cell culture additives to inhibit PARP, for example, in order to radio-sensitize cells to known chemo or ionising radiation treatments in vitro.
- Active compounds may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
- the active compound or pharmaceutical composition comprising the active compound may be administered to a subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g.
- vaginal parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly.
- the subject may be a eukaryote, an animal, a vertebrate animal, a mammal, a rodent (e.g. a guinea pig, a hamster, a rat, a mouse), murine (e.g. a mouse), canine (e.g. a dog), feline (e.g. a cat), equine (e.g. a horse), a primate, simian (e.g. a monkey or ape), a monkey (e.g. marmoset, baboon), an ape (e.g. gorilla, chimpanzee, orangutan, gibbon), or a human.
- a rodent e.g. a guinea pig, a hamster, a rat, a mouse
- murine e.g. a mouse
- canine e.g. a dog
- feline e.g. a cat
- the active compound While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g., formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
- a pharmaceutical composition e.g., formulation
- pharmaceutically acceptable carriers e.g., adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
- the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilisers, or other materials, as described herein.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a subject e.g., human
- Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, losenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, electuaries, or aerosols.
- Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
- a tablet may be made by conventional means, e.g., compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); and preservatives (e.g., methyl p-hydroxybenzoate, propyl
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile.
- Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil.
- a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents.
- Formulations suitable for topical administration in the mouth include losenges comprising the active compound in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.
- Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser include aqueous or oily solutions of the active compound.
- Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- Formulations suitable for topical administration via the skin include ointments, creams, and emulsions.
- the active compound When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base.
- the active compounds may be formulated in a cream with an oil-in-water cream base.
- the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
- the topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
- an emulsifier otherwise known as an emulgent
- a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
- the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate.
- the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
- Suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
- concentration of the active compound in the solution is from about 1 ng/ml to about 10 ⁇ g/ml, for example from about 10 ng/ml to about 1 ⁇ g/ml.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or more organs.
- appropriate dosages of the active compounds, and compositions comprising the active compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight, condition, general health, and prior medical history of the patient.
- the amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration in vivo can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
- a suitable dose of the active compound is in the range of about 100 ⁇ g to about 250 mg per kilogram body weight of the subject per day.
- the active compound is a salt, an ester, prodrug, or the like
- the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
- R E 3-t-butyl-1-(2,4-dichlorobenzyl)pyrazol-5-yl
- R A 4-bromo-1-ethyl-3-methylpyrazol-5-yl
- R A 1-t-butyl-5-methylpyrazol-3-yl
- R A 3,4-dihydro-2H-1,5-benzodioxepin-7-yl
- R A 2-chloro-6-methyl-4-pyridyl
- R A 1-(4-chlorophenoxy)-1-methylethyl
- R A 6-fluoro-1,3-benzodioxan-8-yl
- R A 2,4,5-trifluoro-3-methoxyphenyl
- R A 2-chloro-3,4-dimethoxystyryl
- R A 2-(4-methylphenylthio)-3-pyridyl
- R A 1-benzyloxycarbonylpiperid-4-yl
- R A 1-(4-methoxyphenyl)-5-methylpyrazol-4-yl
- R A 5-(2-pyridyl)-2-thienyl
- R A 3-methyl-5-(5-methylisoxazol-3-yl)isoxazol-4-yl
- R A 2-(2,3-dihydrobenzo[b]furan-5-yl)-4-methylthiazol-5-yl
- R A 5-(4-chlorophenyl)-2-(trifluoromethyl)-3-furyl
- R A 4-(4-chlorophenylsulphonyl)-3-methyl-2-thienyl
- R A 1-benzyl-3-t-butylpyrazol-5-yl
- R A 1-phenylsulphonylindol-3-yl
- Mammalian PARP isolated from Hela cell nuclear extract, was incubated with Z-buffer (25 mM Hepes (Sigma); 12.5 mM MgCl 2 (Sigma); 50 mM KCl (Sigma); 1 mM DTT (Sigma); 10% Glycerol (Sigma) 0.001% NP-40 (Sigma); pH 7.4) in 96 well FlashPlates (TRADE MARK) (NEN, UK) and varying concentrations of said inhibitors added. All compounds were diluted in DMSO and gave final assay concentrations of between 10 and 0.01 ⁇ M, with the DMSO being at a final concentration of 1% per well. The total assay volume per well was 40 ⁇ l.
- % ⁇ ⁇ Inhibition 100 - ( 100 ⁇ ( cpm ⁇ ⁇ of ⁇ ⁇ unknowns - mean ⁇ ⁇ negative ⁇ ⁇ cpm ) ( mean ⁇ ⁇ positive ⁇ ⁇ cpm - mean ⁇ ⁇ neagative ⁇ ⁇ cpm ) )
- IC 50 values the concentration at which 50% of the enzyme activity is inhibited
- concentration at which 50% of the enzyme activity is inhibited are determined over a range of different concentrations, normally from 10 ⁇ M down to 0.01 ⁇ M.
- Such IC 50 values are used as comparative values to identify increased compound potencies.
- the IC 50 of 100 (1(2H)-phthalazinone was determined using the above test to be 7.2 ⁇ M.
- the Dose Enhancing Factor is a ratio of the enhancement of cell growth inhibition elicited by the test compound in the presence of bleomycin compared to bleomycin alone.
- the test compounds were used at a fixed concentration of 25 ⁇ M.
- Bleomycin was used at a concentration of 0.5 ⁇ g/ml.
- the DEF was calculated from the formula:
- Growth TC Growth Control ⁇ Growth bleo Growth ( bleo + TC ) where Growth TC is cell growth in presence of the test compound; Growth Control is cell growth of control cells; Growth bleo is cell growth in presence of bleomycin; and Growth (bleo+TC) is cell growth in presence of bleomycin and the test compound.
- SRB sulforhodamine B
- 2,000 HeLa cells were seeded into each well of a flat-bottomed 96-well microtiter plate in a volume of 100 ⁇ l and incubated for 6 hours at 37° C. Cells were either replaced with media alone or with media containing the test compound at a final concentration of 25 ⁇ M. Cells were allowed to grow for a further 1 hour before the addition of bleomycin to either untreated cells or test compound treated cells. Cells untreated with either bleomycin or test compound were used as a control. Cells treated with test compound alone were used to assess the growth inhibition by the test compound.
- SRB sulforhodamine B
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
- A and B together represent an optionally substituted, fused aromatic ring;
- RC is represented by -L-RL, where L is of formula:
—(CH2)n1-Qn2-(CH2)n3— - wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(═O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are attached in Q, —(CH2)n3— (if present) and part of RL;
- and RL is optionally substituted C5-20 aryl; and
- RN is selected from hydrogen, optionally substituted C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone.
Description
or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:
A and B together represent an optionally substituted, fused aromatic ring;
RC is represented by -L-RL, where L is of formula:
—(CH2)n1-Qn2-(CH2)n3—
wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(═O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are attached in Q, —(CH2)n3— (if present) and part of RL;
and RL is optionally substituted C5-20 aryl; and
RN is selected from hydrogen, optionally substituted C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone.
or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:
A and B together represent an optionally substituted, fused aromatic ring;
RC is —CH2—RL;
RL is optionally substituted phenyl; and
RN is hydrogen.
—(CHn2)n1′-Q′n2′-(CH2)n3′—
wherein n1′, n2′ and n3′ are each selected from 0, 1, 2 and 3 and the sum of n1′, n2′ and n3′ is less than or equal to 3. Q′ can be O, S, NH or C(═O).
Further Preferences
(ii) ureido, where one amine substituent is preferably hydrogen, and the other is selected from C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, more preferably C1-7 alkyl and C5-20 aryl, which groups are optionally further substituted. The optional substituents may be selected from any of those listed above, but those of particular interest include C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, halo and ether groups;
(iii) sulfonamino, wherein the amine substituent is preferably hydrogen and the sulfone substituent is selected from C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, more preferably C1-7 alkyl and C5-20 aryl, which groups are optionally further substituted. The optional substituents may be selected from any of those listed above, but those of particular interest include C5-20 aryl groups and acylamido groups;
(iv) acyloxy, wherein the acyloxy substituent is selected from C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, more preferably C1-7 alkyl and C5-20 aryl, which groups are optionally further substituted. The optional substituents may be selected from any of those listed above, but those of particular interest include C1-7 alkyl and C5-20 aryl groups, halo, ether, thioether, sulfone and nitro groups.
TABLE 1 | |||
Compound | IC50 (μM) | ||
126 | 1.8 | ||
129 | 1.6 | ||
132 | 0.7 | ||
141 | 1.4 | ||
151 | 1.8 | ||
186 | 1.1 | ||
191 | 1.3 | ||
211 | 0.4 | ||
248 | 1.0 | ||
139 | 1.7 | ||
163 | 1.8 | ||
192 | 1.4 | ||
138 | 1.2 | ||
142 | 0.7 | ||
193 | 1.0 | ||
194 | 1.4 | ||
164 | 1.8 | ||
165 | 0.3 | ||
276 | 2.5 | ||
277 | 0.6 | ||
159 | 3.5 | ||
160 | 1.3 | ||
166 | 4.1 | ||
167 | 1.6 | ||
227 | 0.4 | ||
169 | 0.6 | ||
170 | 0.4 | ||
171 | 0.6 | ||
172 | 0.09 | ||
215 | 4.0 | ||
216 | 0.3 | ||
206 | 1.2 | ||
179 | 0.04 | ||
212 | 0.9 | ||
213 | 4.4 | ||
239 | 0.6 | ||
180 | 1.3 | ||
222 | 2.2 | ||
247 | 0.5 | ||
241 | 0.9 | ||
198 | 3.8 | ||
204 | 0.7 | ||
202 | 0.07 | ||
131 | 4.4 | ||
177 | 0.8 | ||
178 | 0.2 | ||
249 | 0.7 | ||
145 | 0.8 | ||
90 | 0.9 | ||
91 | 3.3 | ||
92 | 1.3 | ||
93 | 2.1 | ||
where GrowthTC is cell growth in presence of the test compound;
GrowthControl is cell growth of control cells;
Growthbleo is cell growth in presence of bleomycin; and
Growth(bleo+TC) is cell growth in presence of bleomycin and the test compound.
TABLE 2 | |||
| DEF | ||
126 | 1.9 | ||
129 | 1.3 | ||
132 | 2.3 | ||
141 | 1.6 | ||
151 | 1.9 | ||
186 | 1.6 | ||
191 | 1.5 | ||
211 | 1.4 | ||
248 | 1.2 | ||
139 | 1.4 | ||
163 | 1.3 | ||
192 | 1.4 | ||
138 | 1.3 | ||
142 | 1.6 | ||
193 | 2.2 | ||
194 | 1.6 | ||
164 | 1.3 | ||
165 | 1.3 | ||
160 | 1.5 | ||
166 | 1.4 | ||
227 | 2.6 | ||
169 | 1.5 | ||
170 | 2.6 | ||
171 | 1.8 | ||
172 | 1.4 | ||
215 | 1.4 | ||
216 | 1.3 | ||
206 | 1.2 | ||
179 | 1.4 | ||
212 | 2.3 | ||
213 | 1.3 | ||
180 | 1.2 | ||
222 | 1.2 | ||
198 | 2.3 | ||
204 | 1.6 | ||
131 | 1.3 | ||
177 | 1.2 | ||
178 | 1.9 | ||
145 | 1.8 | ||
90 | 1.8 | ||
91 | 1.4 | ||
92 | 1.5 | ||
93 | 1.3 | ||
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/352,178 US7750006B2 (en) | 2000-10-30 | 2006-02-10 | Phthalazinone derivatives |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0026505.8A GB0026505D0 (en) | 2000-10-30 | 2000-10-30 | Phthalazinone derivatives |
GB0026505.8 | 2000-10-30 | ||
US24566200P | 2000-11-06 | 2000-11-06 | |
US27506601P | 2001-03-12 | 2001-03-12 | |
US10/021,506 US7151102B2 (en) | 2000-10-30 | 2001-10-30 | Phthalazinone derivatives |
US11/352,178 US7750006B2 (en) | 2000-10-30 | 2006-02-10 | Phthalazinone derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,506 Continuation US7151102B2 (en) | 2000-10-30 | 2001-10-30 | Phthalazinone derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
US20060142293A1 US20060142293A1 (en) | 2006-06-29 |
US7750006B2 true US7750006B2 (en) | 2010-07-06 |
Family
ID=27447901
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,506 Expired - Lifetime US7151102B2 (en) | 2000-10-30 | 2001-10-30 | Phthalazinone derivatives |
US11/352,178 Expired - Lifetime US7750006B2 (en) | 2000-10-30 | 2006-02-10 | Phthalazinone derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,506 Expired - Lifetime US7151102B2 (en) | 2000-10-30 | 2001-10-30 | Phthalazinone derivatives |
Country Status (1)
Country | Link |
---|---|
US (2) | US7151102B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100098763A1 (en) * | 2008-10-07 | 2010-04-22 | Astrazeneca Ab | Pharmaceutical formulation 514 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AU2003229953A1 (en) * | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
DK1684736T3 (en) * | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | DNA damage repair inhibitors for cancer treatment |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
WO2007144652A2 (en) * | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | Parp inhibitors |
JP2009541217A (en) * | 2006-06-15 | 2009-11-26 | クドス ファーマシューティカルズ リミテッド | 2-Oxybenzamide derivatives as PARP inhibitors |
WO2007144637A1 (en) * | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | 2 -oxyheteroarylamide derivatives as parp inhibitors |
UY30639A1 (en) * | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS |
US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
PL2120579T3 (en) * | 2006-12-28 | 2014-04-30 | Abbvie Inc | Inhibitors of poly(adp-ribose)polymerase |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
CN101821242B (en) * | 2007-10-17 | 2013-07-24 | 库多斯药物有限公司 | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbony_, -fluoro-benzyl] -2h-phthalaz in-1-one |
EP2214667A2 (en) * | 2007-10-22 | 2010-08-11 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
UY31603A1 (en) | 2008-01-23 | 2009-08-31 | DERIVATIVES OF FTALAZINONA | |
EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
US20110098304A1 (en) * | 2008-10-22 | 2011-04-28 | Bijoy Panicker | Small molecule inhibitors of PARP activity |
AR079774A1 (en) * | 2009-07-15 | 2012-02-22 | Astrazeneca Ab | FTALAZINONE COMPOSITE AS CRYSTALINE FORM C, PHARMACEUTICAL COMPOSITION AND USES OF THE SAME |
JP2013526514A (en) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | Lipoic acid and nitroxide derivatives and uses thereof |
US8722731B2 (en) | 2010-06-07 | 2014-05-13 | Novomedix, Llc | Furanyl compounds and the use thereof |
EP3925962A1 (en) * | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
CN103130723B (en) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | Poly (aenosine diphosphate glucose pyrophospheralase (ADP)-ribose) polymerase inhibitor |
US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
PT3475272T (en) | 2016-06-24 | 2023-12-15 | Univ California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
US10519136B2 (en) | 2017-12-29 | 2019-12-31 | Accutar Biotechnology | Dual inhibitors of PARP1 and CDK |
TWI820077B (en) | 2018-01-05 | 2023-11-01 | 美商斯布雷克薩一號公司 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
CN114026085A (en) | 2019-04-11 | 2022-02-08 | 安吉昂生物医药公司 | (E) Solid forms of (E) -3- [2- (2-thienyl) vinyl ] -1H-pyrazole |
EP3996749A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
CA3161892A1 (en) | 2019-12-23 | 2021-07-01 | Jie Fan | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
KR102347516B1 (en) | 2020-05-12 | 2022-01-04 | 한국화학연구원 | Compound for inhibiting PARP and medical use thereof |
WO2022150596A1 (en) | 2021-01-08 | 2022-07-14 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Citations (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE287032C (en) | ||||
GB721286A (en) | 1951-02-16 | 1955-01-05 | Smith Kline & French Internat | Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives |
DE2143745A1 (en) | 1971-09-01 | 1973-03-08 | Hoechst Ag | 3,4-DIHYDRO-2H-ISOCHINOLIN-1-THIONE AND THE METHOD FOR MANUFACTURING IT |
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
FR2262513B1 (en) | 1974-03-01 | 1978-07-21 | Delalande Sa | |
EP0030861A2 (en) | 1979-12-18 | 1981-06-24 | Pfizer Inc. | Isoquinoline acetic acids and pharmaceutical compositions thereof |
US4665181A (en) | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
EP0269968A2 (en) | 1986-11-28 | 1988-06-08 | Dr. Karl Thomae GmbH | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation |
DE3813531A1 (en) | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Novel 2-aminoalkyl-4-benzyl-1-(2H)-phthalazinone derivatives |
US4841047A (en) | 1985-11-11 | 1989-06-20 | Aasta Pharma Ag | 4-benzyl-1-(2H)-phthalazinone-derivates |
EP0355750A1 (en) | 1988-08-19 | 1990-02-28 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
EP0389995A2 (en) | 1989-03-28 | 1990-10-03 | Nisshin Flour Milling Co., Ltd. | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
EP0590551A2 (en) | 1992-10-02 | 1994-04-06 | ASTA Medica Aktiengesellschaft | New therapeutic uses of phthalazinone-derivatives |
EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
EP0699754A1 (en) | 1994-08-12 | 1996-03-06 | Myriad Genetics, Inc. | Method for diagnosing a predisposition for breast and ovarian cancer |
EP0705903A1 (en) | 1994-08-12 | 1996-04-10 | Myriad Genetics, Inc. | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
EP0792643A1 (en) | 1996-02-29 | 1997-09-03 | Pfizer Inc. | Use of an aldose reductase inhibitor for reducing non-cardiac tissue damage |
US5817674A (en) | 1991-02-07 | 1998-10-06 | Roussel Uclaf | Quinoline compounds |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5874444A (en) | 1994-12-21 | 1999-02-23 | Geron Corporation | Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5880128A (en) | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5886178A (en) | 1996-05-30 | 1999-03-23 | Syntex (U.S.A.) Inc. | 3-aroylbenzylpyridazinone derivatives |
US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US20010029258A1 (en) | 1998-06-30 | 2001-10-11 | Snutch Terrance P. | Partially saturated calcium channel blockers |
US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
US6340684B1 (en) | 1998-07-21 | 2002-01-22 | Zambon Group S.P.A. | Phthalazine derivatives as phosphodiesterase 4 inhibitors |
US6387897B1 (en) | 1998-06-30 | 2002-05-14 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US20020183325A1 (en) | 2000-10-30 | 2002-12-05 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20030022819A1 (en) | 2000-06-16 | 2003-01-30 | Ling Leona E. | Angiogenesis-modulating compositions and uses |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6514984B1 (en) | 1997-11-14 | 2003-02-04 | Eli Lilly And Company | Treatment for alzheimer's disease |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US20030195195A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6677333B1 (en) | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US20040023968A1 (en) | 2002-04-30 | 2004-02-05 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20040034035A1 (en) | 1998-06-30 | 2004-02-19 | Neuromed Technologies, Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
GB2384776B (en) | 2000-10-30 | 2004-03-03 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20040044004A1 (en) | 1998-06-30 | 2004-03-04 | Neuromed Technologies, Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US20040147529A1 (en) | 1998-06-30 | 2004-07-29 | Snutch Terrance P. | Preferentially substituted calcium channel blockers |
EP1477175A1 (en) | 2002-02-19 | 2004-11-17 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
US20040259866A1 (en) | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
US20040266784A1 (en) | 1998-06-30 | 2004-12-30 | Snutch Terrance P. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US20050020583A1 (en) | 2001-08-07 | 2005-01-27 | Maurizio Pulici | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
US20050054568A1 (en) | 2000-06-16 | 2005-03-10 | Ling Leona E. | Angiogenesis-modulating compositions and uses |
US20050059663A1 (en) | 2003-03-12 | 2005-03-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20050080096A1 (en) | 2002-01-29 | 2005-04-14 | Junya Ishida | Condensed heterocyclic compounds |
US6891041B2 (en) | 1999-12-23 | 2005-05-10 | Orlin Petrov | Method for producing 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones |
US6953857B2 (en) | 2000-12-23 | 2005-10-11 | Aventis Pharma Deutschland Gmbh | Oxybenzamide derivatives useful for inhibiting factor Xa or viia |
US20050227999A1 (en) | 2004-04-09 | 2005-10-13 | Neuromed Technologies Inc. | Diarylamine derivatives as calcium channel blockers |
US20050227919A1 (en) | 2003-12-01 | 2005-10-13 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for the treatment of cancer |
US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US20060063767A1 (en) | 2004-08-26 | 2006-03-23 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
US20060084660A1 (en) | 1998-06-30 | 2006-04-20 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
US20060276391A1 (en) | 2004-12-03 | 2006-12-07 | Alberto Auricchio | Use of compounds that interfere with the Hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
EP1760071A1 (en) | 2004-06-23 | 2007-03-07 | Ono Pharmaceutical Co., Ltd. | Compound having s1p receptor binding potency and use thereof |
US20070093489A1 (en) | 2005-10-19 | 2007-04-26 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20080146575A1 (en) | 2006-10-17 | 2008-06-19 | Keith Allan Menear | Phthalazinone derivatives |
WO2008083027A1 (en) | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
US20080255128A1 (en) | 2007-04-10 | 2008-10-16 | Muhammad Hashim Javaid | Phthalazinone derivatives |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8610018D0 (en) | 1986-04-24 | 1986-05-29 | Fujisawa Pharmaceutical Co | Phthalazine derivatives |
GB9011833D0 (en) | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
CA2147504A1 (en) | 1992-11-02 | 1994-05-11 | Prasun K. Chakravarty | Substituted phthalazinones as neurotensin antagonists |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
US5888529A (en) | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
EP1066039A4 (en) | 1998-03-02 | 2003-02-26 | Cocensys Inc | Substituted quinazolines and analogs and the use thereof |
DE19921567A1 (en) | 1999-05-11 | 2000-11-16 | Basf Ag | Use of phthalazine derivatives |
US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
ECSP003637A (en) | 1999-08-31 | 2002-03-25 | Agouron Pharma | TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES |
AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
TR200101499T1 (en) | 1999-09-28 | 2002-09-23 | Basf Aktiengesellschaft | Azepinoindole derivatives, their preparation and uses. |
WO2001057038A1 (en) | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterocyclic compounds and their use as parp inhibitors |
AU2001248748A1 (en) | 2000-04-18 | 2001-10-30 | Sumitomo Pharmaceuticals Company, Limited | Substituted piperazine compounds |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
DE10022925A1 (en) | 2000-05-11 | 2001-11-15 | Basf Ag | New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus |
WO2001087845A2 (en) | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
WO2002068407A1 (en) | 2001-02-28 | 2002-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole compound |
JP2004528376A (en) | 2001-05-08 | 2004-09-16 | クドス ファーマシューティカルズ リミテッド | Isoquinolinone derivatives as PARP inhibitors |
EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
AU2002358650A1 (en) | 2001-12-14 | 2003-06-30 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
WO2003057145A2 (en) | 2001-12-31 | 2003-07-17 | Guilford Pharmaceuticals Inc. | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
PT1485377E (en) | 2002-02-25 | 2010-03-12 | Kudos Pharm Ltd | Pyranones useful as atm inhibitors |
AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
-
2001
- 2001-10-30 US US10/021,506 patent/US7151102B2/en not_active Expired - Lifetime
-
2006
- 2006-02-10 US US11/352,178 patent/US7750006B2/en not_active Expired - Lifetime
Patent Citations (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE287032C (en) | ||||
GB721286A (en) | 1951-02-16 | 1955-01-05 | Smith Kline & French Internat | Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives |
DE2143745A1 (en) | 1971-09-01 | 1973-03-08 | Hoechst Ag | 3,4-DIHYDRO-2H-ISOCHINOLIN-1-THIONE AND THE METHOD FOR MANUFACTURING IT |
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
FR2262513B1 (en) | 1974-03-01 | 1978-07-21 | Delalande Sa | |
EP0030861A2 (en) | 1979-12-18 | 1981-06-24 | Pfizer Inc. | Isoquinoline acetic acids and pharmaceutical compositions thereof |
US4665181A (en) | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US4841047A (en) | 1985-11-11 | 1989-06-20 | Aasta Pharma Ag | 4-benzyl-1-(2H)-phthalazinone-derivates |
EP0269968A2 (en) | 1986-11-28 | 1988-06-08 | Dr. Karl Thomae GmbH | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation |
DE3813531A1 (en) | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Novel 2-aminoalkyl-4-benzyl-1-(2H)-phthalazinone derivatives |
EP0355750A1 (en) | 1988-08-19 | 1990-02-28 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
EP0389995A2 (en) | 1989-03-28 | 1990-10-03 | Nisshin Flour Milling Co., Ltd. | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US5817674A (en) | 1991-02-07 | 1998-10-06 | Roussel Uclaf | Quinoline compounds |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
US5556856A (en) | 1992-10-02 | 1996-09-17 | Asta Medica Aktiengesellschaft | Phthalazinone derivatives that modulate multi-drug resistance |
EP0590551A2 (en) | 1992-10-02 | 1994-04-06 | ASTA Medica Aktiengesellschaft | New therapeutic uses of phthalazinone-derivatives |
EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
EP0705903A1 (en) | 1994-08-12 | 1996-04-10 | Myriad Genetics, Inc. | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
EP0699754A1 (en) | 1994-08-12 | 1996-03-06 | Myriad Genetics, Inc. | Method for diagnosing a predisposition for breast and ovarian cancer |
US5874444A (en) | 1994-12-21 | 1999-02-23 | Geron Corporation | Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
EP0792643A1 (en) | 1996-02-29 | 1997-09-03 | Pfizer Inc. | Use of an aldose reductase inhibitor for reducing non-cardiac tissue damage |
US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6051574A (en) | 1996-04-03 | 2000-04-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5880128A (en) | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
US5886178A (en) | 1996-05-30 | 1999-03-23 | Syntex (U.S.A.) Inc. | 3-aroylbenzylpyridazinone derivatives |
US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6514984B1 (en) | 1997-11-14 | 2003-02-04 | Eli Lilly And Company | Treatment for alzheimer's disease |
US6951862B2 (en) | 1998-06-30 | 2005-10-04 | Neuromed Technologies, Inc. | Calcium channel blockers comprising two benzhydril moieties |
US20030045530A1 (en) | 1998-06-30 | 2003-03-06 | Snutch Terrance P. | Preferentially substituted calcium channel blockers |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
US7186726B2 (en) | 1998-06-30 | 2007-03-06 | Neuromed Pharmaceuticals Ltd. | Preferentially substituted calcium channel blockers |
US7064128B2 (en) | 1998-06-30 | 2006-06-20 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
US20060084660A1 (en) | 1998-06-30 | 2006-04-20 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
US20040034035A1 (en) | 1998-06-30 | 2004-02-19 | Neuromed Technologies, Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US20070185105A1 (en) | 1998-06-30 | 2007-08-09 | Snutch Terrance P | Calcium channel blockers |
US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
US20010029258A1 (en) | 1998-06-30 | 2001-10-11 | Snutch Terrance P. | Partially saturated calcium channel blockers |
US6387897B1 (en) | 1998-06-30 | 2002-05-14 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
US6949554B2 (en) | 1998-06-30 | 2005-09-27 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
US6943168B2 (en) | 1998-06-30 | 2005-09-13 | Neuromed Technologies Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US6617322B2 (en) | 1998-06-30 | 2003-09-09 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
US20040266784A1 (en) | 1998-06-30 | 2004-12-30 | Snutch Terrance P. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US20040259866A1 (en) | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
US6294533B1 (en) | 1998-06-30 | 2001-09-25 | Neuormed Technologies, Inc. | Calcium channel blockers |
US20040209872A1 (en) | 1998-06-30 | 2004-10-21 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
US20040192703A1 (en) | 1998-06-30 | 2004-09-30 | Snutch Terrance P. | Preferentially substituted calcium channel blockers |
US20040147529A1 (en) | 1998-06-30 | 2004-07-29 | Snutch Terrance P. | Preferentially substituted calcium channel blockers |
US20040044004A1 (en) | 1998-06-30 | 2004-03-04 | Neuromed Technologies, Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US6498160B2 (en) | 1998-07-21 | 2002-12-24 | Zambon Group S.P.A. | Phthalazine derivatives as phosphodiesterase 4 inhibitors |
US6340684B1 (en) | 1998-07-21 | 2002-01-22 | Zambon Group S.P.A. | Phthalazine derivatives as phosphodiesterase 4 inhibitors |
US6677333B1 (en) | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US7071180B2 (en) | 1999-05-21 | 2006-07-04 | Biovitrum Ab | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US20040242554A1 (en) | 1999-05-21 | 2004-12-02 | Biovitrum, Ab, A Stockholm, Sweden Corporation | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US20030092694A1 (en) | 1999-05-21 | 2003-05-15 | Biovitrum, Ab, A Stockholm, Sweden Corporation | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
US20040023949A1 (en) | 1999-10-14 | 2004-02-05 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6891041B2 (en) | 1999-12-23 | 2005-05-10 | Orlin Petrov | Method for producing 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones |
US20030022819A1 (en) | 2000-06-16 | 2003-01-30 | Ling Leona E. | Angiogenesis-modulating compositions and uses |
US20050054568A1 (en) | 2000-06-16 | 2005-03-10 | Ling Leona E. | Angiogenesis-modulating compositions and uses |
GB2384776B (en) | 2000-10-30 | 2004-03-03 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20020183325A1 (en) | 2000-10-30 | 2002-12-05 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US6953857B2 (en) | 2000-12-23 | 2005-10-11 | Aventis Pharma Deutschland Gmbh | Oxybenzamide derivatives useful for inhibiting factor Xa or viia |
US7067665B2 (en) | 2000-12-23 | 2006-06-27 | Sanofi-Aventis Deutschland Gmbh | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla |
US20050020583A1 (en) | 2001-08-07 | 2005-01-27 | Maurizio Pulici | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
US20050080096A1 (en) | 2002-01-29 | 2005-04-14 | Junya Ishida | Condensed heterocyclic compounds |
EP1477175A1 (en) | 2002-02-19 | 2004-11-17 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
US20030195195A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US20060030557A1 (en) | 2002-04-05 | 2006-02-09 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
US20040023968A1 (en) | 2002-04-30 | 2004-02-05 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20050059663A1 (en) | 2003-03-12 | 2005-03-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20050227919A1 (en) | 2003-12-01 | 2005-10-13 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for the treatment of cancer |
US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US20050227999A1 (en) | 2004-04-09 | 2005-10-13 | Neuromed Technologies Inc. | Diarylamine derivatives as calcium channel blockers |
EP1760071A1 (en) | 2004-06-23 | 2007-03-07 | Ono Pharmaceutical Co., Ltd. | Compound having s1p receptor binding potency and use thereof |
US20060063767A1 (en) | 2004-08-26 | 2006-03-23 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
US20060276391A1 (en) | 2004-12-03 | 2006-12-07 | Alberto Auricchio | Use of compounds that interfere with the Hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
US20070093489A1 (en) | 2005-10-19 | 2007-04-26 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20080146575A1 (en) | 2006-10-17 | 2008-06-19 | Keith Allan Menear | Phthalazinone derivatives |
WO2008083027A1 (en) | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
US20080255128A1 (en) | 2007-04-10 | 2008-10-16 | Muhammad Hashim Javaid | Phthalazinone derivatives |
Non-Patent Citations (188)
Title |
---|
Affar, E. B. et al., Anal. Biochem., 1998, vol. 259, No. 2, 280-3. |
Al-Dabbagh and Smith, "Species differences in oxidative drug metabolism: some basic considerations." Archives of toxicology, Supplement. Archiv fur Toxikologie. Supplement, vol. 7, 219-231 (1984). |
Ame , Bioessays (2004) 26(8):882-893. |
Ame et al., J. Biol. Chem., 1999, vol. 274, 17860-17868. |
Angell et al., EMBO J., 1997, vol. 16, No. 12, 3675-3684. |
Arnaudeau, C. et al., J. Mol. Biol, 2001, vol. 307, 1235-45. |
Banasik, M. et al., "Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferse", J. Biol. Chem., 1992, vol. 267, 1569-1575. |
Banasik, M. et al., Mol. Cell Biochem., 1994, vol. 138, 185-197. |
Banker et al., "Modern Pharmaceuticals", 3rd Ed., p. 596 (1996). * |
Ben-Hur et al., 1984, British Journal of Cancer, 49 (Suppl. VI): 39-42. |
Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., vol. 66, 1-19. Protective Groups in Organic Synthesis (T. Green and P. Wuts, Wiley, 1991). |
Berger, N. A. et al., "Poly (ADP-ribose) in cellular response to DNA damage", Radiation Research, 1985, vol. 101, 4-14. |
Bhattacharyya, A. et al., J. Biol. Chem., 2000, vol. 275, 23899-903. |
Bloch, W. et al., "Poly-adenosine diphosphate-ribose polymerase inhibition for myocardial protection: pathophysiologic and physiologic considerations," J. Thoracic Card. Surg. (2004) 128(2):323-324. |
Bold et. al., J. Med. Chem., 2000, 43, 3200. |
Bold, G. et al., "New anilinophthalazines as potent and orally well absorbed inhibitors of the FEBF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis", J. Med. Chem., 2000, vol. 43, No. 12, 2310-2323. |
Bowman et al., "Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro," British Journal of Cancer, vol. 84(1), 106-112 (2001). |
Braga, D. et al., "Making crystals from crystals: a green route to crystal engineering and polymorphism," Chem. Commun. (2005) 3635-3645. |
Brummelkamp, T. R. et al., Science, 2002, vol. 296, 550-553. |
Bundgaard, H., Design of Prodrugs, 1 (1985) Elsevier Science Publishers. |
Burzio, L. et al., "Poly (adenosine diphosphoribose) synthase activity of isolated nuclei of normal and leukemic leukocytes (38930)", Proc. Soc. Exp. Bio. Med., 1975, vol. 149, 933-938. |
Calabrese, Clin. Cancer Res. (2003) 9:2711-2718. |
Caldecott, Cell (2003) 112:7-10. |
Cantoni, O. et al., "Hydrogen peroxide insult in cultured mammalian cells: relationships between DNA single-strand breakage, poly (ADP-ribose) metabolism and cell killing", Biochim. Biophys. Acta, 1989, vol. 1014, 1-7. |
Catteau, A. et al., Oncogene, 1999, vol. 18, 1957-65. |
Chalmers, Clin. Oncol. (2004) 16(1):29-39. |
Chappuis, P. O. et al., Cancer Treat. Res., 2002, vol. 107, 29-59. |
Chiarugi, Trends Pharmacol. Sci. (2002) 23:122-129. |
Cockcroft, X-L. et al., "Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose) polymerase," Biorg. Med. Chem. Lett. (2006) 16:1040-1044. |
Cosi, C. et al., "Poly (ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells", J Neurosci. Res., 1994, vol. 39, 38-46. |
Cosi, C., "New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets," Expert Opin. Ther. Patents (2002) 12(7): 1047-1071. |
Couzin, J., Science, 2003, vol. 302, 591-592. |
Crooke, Ann. Rev. Pharmacol. Toxicol., 1992, vol. 32, 329-76. |
Cuzzocrea, S., "Shock, inflammation and PARP," Pharmacological Res. (2005) 52:72-82. |
D'Adda Di Fagagna, F. et al., "Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability", Nature Gen., 1999, vol. 23, No. 1, 76-80. |
D'Amours, D. et al., "Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions", Biochem. J., 1999, vol. 342, 249-268. |
D'Amours, Nat. Rev. Mol. Cell Biol. (2002) 3:317-327. |
D'Andrea, A. D. et al., Nat. Rev. Cancer, 2003, vol. 3, 23-34. |
Dantzer, Biochimie (1999) 81:69-75. |
Dantzer, F. et al., Biochemistry, 2000, vol. 39, 7559-69. |
Davies, A. A. et al., Mol. Cell, 2001, vol. 7, 273-82. |
Dillon, K. J. et al., J. Biomolecular Screening, 2003, vol. 8, No. 3, 347-52. |
Durkacz, B. W. et al., "(ADP-ribose)n participates in DNA excision repair", Nature, 1980, vol. 283, No. 7, 593-596. |
Dusemund, "Isochino [3,2-a]phthalazin-5,8-dione", Arch. Pharm., (Weinhein) 1982, pp. 925-930. (English Abstract). |
Dusemund, Arch. Pharm. (1988) 321(1):41-44. |
Egawa, Int. J. Cancer (2001) 95(4):255-259. |
Egawa, Oncology (2001) 61(4):293-298. |
Ehrlich et al., Science, 1991, vol. 252, 1643-50. |
Elbashir, S. M. et al., Nature, 2001, vol. 411, 494-98. |
El-Tamaty et al., Synthesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives, Indian J. Chemistry, v. 35B, 1067-1072 (1996). |
El-Tamaty, Chem. Abs. (1996) 125(23):300924j. |
Esteller, M. et al., J. Natl. Cancer Inst., 2000, vol. 92, 564-9. |
Ferraris, J. et al., Med. Chem. (2003) 46:3138-3151. |
Fire, A. et al., Nature, 1998, 391: 806-811. |
Foray et al., EMBO J., 2003, vol. 22, 2860-71. |
From DNA damage and stress signalling to cell death, 2000, Eds. De Murcia, G and Shall, S, Oxford University Press. |
Fujisawa Pharm., Chemical Abstracts, vol. 109:6531 (1988). |
Fuska, J. et al., "New Cytotoxic and antitumor agents," Chemical Abstracts, 104:102050 (1985). |
Gaken, J. A. et al., "Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity", J. Virology, 1996, vol. 70, No. 6, 3992-4000. |
Gale, P.A. et al., "Calixpyrroles II," Coordination Chem. Rev. (2001) 222:57-102. |
Gavezzotti, A., "Are crystal structures predictable?" Acc. Chem. Res. (1994) 27:309-314. |
Greene, T.W. et al., Protective Groups in Organic Synthesis, Chapters 2 and 7, John Wiley & Sons Inc. (1999) p. 17-23 and 494-503. |
Griffin et al., "The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy," Biochim vol. 77, 408-422 (1995). |
Griffin, et al., Nat. Cell Biol. (2000) 2:757-761. |
Grube, et al., Anal. Biochem. (1991) 193:236-239. |
Haber, J. E., Trends Biochem. Sci., 1999, vol. 24, 271-5. |
Hall, I.H. et al., "Cytotoxicity of imides-N-alkyl semicarbazones, thiosemicarbazones, acetylhydrazones and related derivatives," Anti-Cancer Drugs (and abstract 122:204573), V.6, 147-153 (1995). |
Halldorsson, et al., FEBS Lett. (1978) 85:349-352. |
Handbook of Pharmaceutical Additives, 2001, 2 Ed., Synapse Information Resources Inc., Endicott, New York, USA. |
Hawley's Condensed Chemical Dictionary, 13th ed., Van Nostrand Reinhold eds. 716 and 825 (1997). |
Herceg, Mutat. Res. (2001) 477:97-110. |
Hirai, K. et al., "Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers", Cancer Res., 1983, vol. 43, 3441-3446. |
Hiramoto, T. et al., Oncogene, 1999, vol. 18, 3422-6. |
Hoeijmakers, J. H., Nature, 2001, vol. 411, 366-74. |
Hughes-Davies et al., Cell (2003) 115:523-535. |
Iino, M. et al., "Rational design and evaluation of new lead compound structures for selective .beta.ARK1 inhibitors," J. Med. Chem. (2002) 45(11):2150-2159. |
Islam et al., Chemical Abstracts, vol. 87:67943 (1977). |
Islam et al., Chemical Abstracts, vol. 95:187182 (1981). |
Islam et al., Chemical Abstracts, vol. 95:62106 (1981). |
Jackson, Carcinogenesis (2002) 23:687-696. |
Janatova, M. et al., Neoplasma, 2003, vol. 50, No. 4, 246-50. |
Jancarkova, N., Ceska Gynekol., 2003, vol. 68, No. 1, 11-16. |
Jantzen and Robinson, "B. Prodrugs," taken from Modern Pharmaceuticals, Third Edition, Banker and Rhodes, editors (1996) p. 596. |
Jasin, M., Oncogene, 2002, vol. 21, No. 58, 8981-93. |
Jijon, et al., Am. J. Phsiol. Gastrointest. Liver Physiol. (2000) 279:G641-G651. |
Johnson, et al., Nature (1999) 401:397-399. |
Kanaar, et al., Trends Cell Biol. (1998) 8:483-489. |
Kashani-Sabet et al., Cancer Gene Therapy, 1995, vol. 2, No. 3, 213-223. |
Kawamura, I. et al., "Ponalrestat, an aldose reductase inhibitor," Chemical Abstract 132:273943, 1996. |
Kerr, P. et al., Curr. Biol., 2001, vol. 11, R668-76. |
Kerrigan, F. et al., Poster at 12th SCI-RSC Medicinal Chemistry Symposium, Cambridge, 7-10 (2003). |
Khanna, K. K. et al., Nat. Genet., 2001, vol. 27, No. 3, 247-54. |
Kraakman-Van Der Zwet, M. et al., Mol. Cell Biol., 2002, vol. 22, 669-79. |
Kuperstein et al., Clin. Genet. (2000) 57(3):213-220. |
Kupper et al., Cancer Res. (1996) 56:2715-2717. |
Lakhani, S. R. et al., J. Clin. Oncol., 2002, vol. 20, 2310-18. |
Le Rhun, Y. et al., "Cellular responses to DNA damage in the absence of poly(ADP-ribose)polymerase", Biochem. Biophys. Res. Commun., 1998, vol. 245, 1-10. |
Lemay, M. et al., Biotechniques, 1999, vol. 27, 846-51. |
Liaudet, L. et al., "Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase", Proc. Natl. Acad. Sci. U.S.A., 2000, vol. 97, No. 3, 10203-10208. |
Lindahl, Science (1999) 286:1897-1905. |
Lindahl, Trends Biochem. Sci. (1995) 20:405-411. |
Loh, V.M. et al., "Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase," Bioorg. Med. Chem. Lett. (2005) 15:2235-2238. |
Lundin et al., J. Mol. Biol. (2003) 328:521-535. |
Lundin et al., Mol. Cell Biol. (2002) 22:5869-5878. |
Magnussonet al., Mutagenesis (1990) 5:511-514. |
Martin, N. et al., "Phthalazinone derivatives as potent PARP-1 inhibitors", 13th Intl. Symposium on ADP-ribosylation, 2001, Abstract 107. |
Martin, N. et al., J. Photochem. and PhotoBiol. B: Biology, 2001, vol. 63, 162-170. |
Matsuda, M. et al., Oncogene, 1999, vol. 18, 3427-30. |
McNealy et al., Anticancer Res. (2003) 23:1473-1478. |
Menear, K.A. et al., "4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1," J. Med. Chem. (Published on Web Sep. 19, 2008) 11 pages (A-K). |
Menissier De Murcia, EMBO J. (2003) 22(9):2255-2263. |
Menissier De Murcia, J. et al., "Requirement of poly(ADP-ribose)polymerase in recovery from DNA damage in mice and cells", Proc. Natl. Acad. Sci. U.S.A., 1997, vol. 94, 7303-7307. |
Mercola, et al., Cancer Gene Therapy, 1995, vol. 2, No. 1, 47-59. |
Miller, B.A., "Inhibition of TRPM2 function by PARP inhibitors protects cells from oxidative stress-induced death," Br. J. Pharmacology (2004) 143:515-516. |
Miwa, M. et al., "Cell density-dependent increase in chromatin-associated ADP-ribosyltransferase activity in simian virus 40-transformed cells", Arch. Biochem. Biophys., 1977, vol. 181, 313-321. |
Morrison et al., Nature Gen. (1997) 17:479-482. |
Moynahan, M. E. et al., Mol. Cell, 1999, vol. 4, 511-8. |
Moynahan, M. E. et al., Mol. Cell, 2001, vol. 7, 263-72. |
Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 1987, vol. 51, 263-273. |
Nakamura et al., Nucleic Acids Res. (2003) 31:e104. |
Nathanson, K. L. et al., Nat. Med., 2001, vol. 7, 552-6. |
Neuhausen, S. L. et al., Genet. Test, 1997, vol. 1, 75-83. |
Noel, G. et al., BMC Cell Biol., 2003, vol. 4, 7-17. |
Pacher et al., "The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in Diabetes," Diabetes, 51:514-521 (2002). |
Perkins, E. et al., "Novel inhibitors of poly(ADP-ribose)polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast", Cancer Res., vol. 61, 4175-4183 (2001). |
Pierce et al., Genes Dev. (1999) 13:2633-2638. |
Radice, P. J., Exp. Clin. Cancer Res., 2002, vol. 21 (3 Suppl.), 9-12. |
Rattan, S. I. et al., "Kinetin delays the onset of ageing characteristics in human fibroblasts", Biochem. Biophys. Res. Commun., 1994, vol. 201, No. 2, 665-672. |
Said, S. I. et al., "Excitotoxicity in the lung: N-methy-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose)polymerase", Proc. Natl. Acad. Sci. U.S.A., 1996, vol. 93, 4688-4692. |
Samper et al., J. Cell. Biol. (2001) 154:49-60. |
Satoh et al., Nature (1992) 356:356-358. |
Schlicker, A. et al., "4-Amino-1,8-napthalimide: a novel inhibitor of poly(ADP-ribose)polymerase and radiation sensitizer", Int. J. Radiat. Bio., 1999, vol. 75, No. 1, 91-100. |
Schreiber et al., J. Biol. Chem. (2002) 277:23028-23036. |
Schreiber, PNAS USA (1995) 92:4753-4757. |
Schultz, N. et al., Nucleic Acids Res., 2003, vol. 31, 4959-64. |
Seminov et al., Nucleic Acids Res. (1999) 27:4526-4531. |
Shah et al., Biochim. Biophys. Acta. Mol. Cell Res. (1996) 1312:1-7. |
Shall, S. et al., Mutat. Res., 2000, vol. 460, 1-15. |
Shimizu, T. et al., "Inhibitory effects of azelastine and tranilast on leukotriene B4 and leukotriene C4 generation by rat colonic mucosa", Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, vol. 53, 355-358. |
Silverman, R.B., The Organic Chemistry of Drug Design and Drug Action, 352-400 (1992) Academic Press, Inc. |
Simbulan-Rosenthal, PNAS USA (1999) 96:13191-13196. |
Skehan, P. et al., "New colorimetric cytotoxicity assay for anticancer-drug screening", J. Natl. Cancer Inst., 1990, vol. 82, No. 13, 1107-1112. |
Southan, G.J. and Szabo, C., "Poly (ADP-ribose) polymerase inhibitors," Current Medicinal Chemistry, 10:4, 321-340 (2003). |
Suto et al., Anticancer Drug Des., 1991, vol. 6, 107-17. |
Szabo, "PARP as a Therapeutic Target," Zhang, Ed. CRC Press (2002) 169-204. |
Szabo, C. et al., "Endothelial dysfunction in a rat model of endotoxic shock", J. Clin. Invest., 1997, vol. 100, 723-25. |
Szabo, G. et al., "Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest," J. Thoracic Cardiovas. Surg. (2003) 126(3):651-658. |
Taniguchi, T. et al., Nat. Med., 2003, vol. 9, 568-74. |
Tarsounas, M. et al., Oncogene, 2003, vol. 22, 1115-23. |
Tasatargil, A. et al., "Poly(ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta," Pharmacology (2004) 72:99-105. |
Tebbs, PNAS USA (1995) 92:6354-6358. |
Tentori, Pharmacol. Res. (2002) 45:73-85. |
Thompson, L. H. et al., Mutat. Res., 2002, vol. 509, 49-78. |
Tracey, W. et al., "Aldose reductase inhibition alone or combined with an adenosine A3 agonist reduces ischemic myocardial injury," Chemical Abstract (2000) 134:65983. |
Tutt et al., EMBO J., 2001, vol. 20, 4704-16. |
Tutt et al., EMBO Rep., 2002, vol. 3, 255-60. |
Tutt, et al., Trends Mol. Med., 2002, 8(12):571-576. |
Uhlmann et al., Chem. Rev., 1990, vol. 90, 543-584. |
United States Office Action for U.S. Appl. No. 10/021,506, filed Jun. 15, 2005 (5 pages). |
United States Office Action for U.S. Appl. No. 10/021,506, filed Nov. 21, 2005 (8 pages). |
United States Office Action for U.S. Appl. No. 10/021,506, filed Nov. 26, 2003 (5 pages). |
United States Office Action for U.S. Appl. No. 10/021,506, filed Sep. 7, 2004 (7 pages). |
United States Office Action for U.S. Appl. No. 10/426,147, filed Apr. 25, 2006 (14 pages). |
United States Office Action for U.S. Appl. No. 10/426,147, filed Aug. 9, 2005 (16 pages). |
United States Office Action for U.S. Appl. No. 10/426,147, filed Oct. 28, 2004 (32 pages). |
United States Office Action for U.S. Appl. No. 11/873,671, filed Mar. 6, 2009 (12 pages). |
United States Office Action for U.S. Appl. No. 11/873,671, filed Sep. 3, 2008 (35 pages). |
United States Office Action for U.S. Appl. No. 12/143,208, filed May 8, 2009 (17 pages). |
US 6,759,401, 07/2004, Nilsson et al. (withdrawn) |
Van Gent, Nat. Rev. Genet. (2001) 2:196-206. |
Venkitaraman, A. R., Cell, 2002, vol. 108, 171-82. |
Vippagunta, S.R. et al., "Crystalline solids," Adv. Drug Delivery Reviews (2001) 48:3-26. |
Virag and Szabo, "The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors," Pharmacological Reviews, vol. 54(3), (2002) 375-429. |
Voinnet et al., Nature, 1997, vol. 389, 553. |
Waldman, Nucleic Acids Res. (1991) 19:5943-5947. |
Wang, Z.-Q. et al., "Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease", Genes Dev., 1995, vol. 9, 509-520. |
Wang, Z.-Q. et al., Genes Dev., 1997, vol. 11, 2347-58. |
West, A.R. "Solid State Chemistry and its Applications" Wiley, New York, 358 and 365 (1988). |
Wolff, M.E., "Burger's Medicinal Chemistry", 5th Ed., Part 1, pp. 975-977 (1995). * |
Wood et al., Science, 2001, vol. 291, 1284-89. |
Yamaguchi, M. et al., "Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones", J. Med. Chem., 1993, vol. 36, No. 25, 4052-4060. |
Yamaguchi, M. et al., "Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridy1)-1(2H)-phthalazinones", J. Med. Chem., 1993, vol. 36, No. 25, 4061-4068. |
Zamore, P. D., Cell, 2000, vol. 101, 25-33. |
Zamore, P. D., Nature Structural Biology, 2001, vol. 8, 746-50. |
Zhang, Portland Press Proc. (1999) 15:125. |
Zhang, W. et al., "Fluorous 2,4-dichloro-1,3,5-triazine (F-DCT) as amide coupling agent," QSAR Comb Sci. (2006) 25(8-9):724-727. |
Zhong, Q. et al., Science, 1999, vol. 285, 747-50. |
Zingarelli, Immunology (2004) 113(4):509-517. |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100098763A1 (en) * | 2008-10-07 | 2010-04-22 | Astrazeneca Ab | Pharmaceutical formulation 514 |
US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US11633396B2 (en) | 2008-10-07 | 2023-04-25 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
US11975001B2 (en) | 2008-10-07 | 2024-05-07 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
US12048695B2 (en) | 2008-10-07 | 2024-07-30 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Also Published As
Publication number | Publication date |
---|---|
US7151102B2 (en) | 2006-12-19 |
US20060142293A1 (en) | 2006-06-29 |
US20020183325A1 (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7750006B2 (en) | Phthalazinone derivatives | |
CA2423279C (en) | Phthalazinone derivatives | |
US6664269B2 (en) | Isoquinolinone derivatives | |
US11160803B2 (en) | Phthalazinone derivatives | |
US7196085B2 (en) | Phthalazinone derivatives | |
AU2001295789A1 (en) | Phthalazinone derivatives | |
US7407957B2 (en) | Phthalazinone derivatives | |
US7662818B2 (en) | Phthalazinone derivatives | |
ZA200302112B (en) | Phthalazinone derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: KUDOS PHARMACEUTICALS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAYBRIDGE LIMITED;REEL/FRAME:031487/0561 Effective date: 20130927 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |